Clinical Trial

A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2025 (before its estimated March 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.
Trial Details
NCT Number NCT07294235
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Collaborators: BrightGene Pharmaceutical Co., Ltd.
Conditions Overweight or Obesity
Enrollment 60 participants
Start Date 2025-12-05
Primary Completion 2026-03-02 (estimated)
Study Completion 2026-03-02 (estimated)
Updated on ClinicalTrials.gov 2025-12-19